Switch theme
Sign up to access all valuation multiples
aXichem AB develops and delivers nature-identical ingredients of the highest purity. The company offers axiphen-feed used in the breeding of chickens and pigs, Bio-repellents used to repel unwanted biological organisms from installations or areas, and aXivite an alternative to capsaicin.
1999
7
Last FY Revenue $0.9M
Last FY EBITDA -$1.2M
$15.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, aXichem achieved revenue of $0.9M and an EBITDA of -$1.2M.
aXichem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See aXichem valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.9M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 83% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -135% | XXX | XXX | XXX |
| EBIT | XXX | -$1.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -185% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.8M | XXX | XXX | XXX |
| Net Margin | XXX | -208% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, aXichem's stock price is SEK 3 (or $0).
aXichem has current market cap of SEK 160M (or $16.5M), and EV of SEK 146M (or $15.0M).
See aXichem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.0M | $16.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, aXichem has market cap of $16.5M and EV of $15.0M.
aXichem's trades at 17.0x EV/Revenue multiple, and -12.6x EV/EBITDA.
Equity research analysts estimate aXichem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
aXichem's P/E ratio is not available.
See valuation multiples for aXichem and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16.5M | XXX | $16.5M | XXX | XXX | XXX |
| EV (current) | $15.0M | XXX | $15.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 17.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -12.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -9.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialaXichem's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
aXichem's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
aXichem's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for aXichem and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -135% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 267% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
aXichem acquired XXX companies to date.
Last acquisition by aXichem was XXXXXXXX, XXXXX XXXXX XXXXXX . aXichem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was aXichem founded? | aXichem was founded in 1999. |
| Where is aXichem headquartered? | aXichem is headquartered in Sweden. |
| How many employees does aXichem have? | As of today, aXichem has 7 employees. |
| Is aXichem publicy listed? | Yes, aXichem is a public company listed on STO. |
| What is the stock symbol of aXichem? | aXichem trades under AXIC A ticker. |
| When did aXichem go public? | aXichem went public in 2011. |
| Who are competitors of aXichem? | Similar companies to aXichem include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of aXichem? | aXichem's current market cap is $16.5M |
| Is aXichem profitable? | Yes, aXichem is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
